Lifesci Capital Has Pessimistic View of TCRX FY2024 Earnings

TScan Therapeutics, Inc. (NASDAQ:TCRX) – Equities research analysts at Lifesci Capital reduced their FY2024 EPS estimates for shares of TScan Therapeutics in a research report issued on Tuesday, November 12th. Lifesci Capital analyst S. Slutsky now anticipates that the company will post earnings of ($1.08) per share for the year, down from their prior estimate of ($1.07). The consensus estimate for TScan Therapeutics’ current full-year earnings is ($1.17) per share. Lifesci Capital also issued estimates for TScan Therapeutics’ FY2025 earnings at ($1.08) EPS.

TScan Therapeutics (NASDAQ:TCRX) last issued its earnings results on Tuesday, November 12th. The company reported ($0.25) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.28) by $0.03. TScan Therapeutics had a negative return on equity of 58.72% and a negative net margin of 1,188.88%. The firm had revenue of $1.05 million for the quarter, compared to analysts’ expectations of $2.86 million.

Several other equities research analysts have also recently weighed in on the stock. HC Wainwright restated a “buy” rating and issued a $15.00 price target on shares of TScan Therapeutics in a research report on Friday. Wedbush restated an “outperform” rating and issued a $10.00 target price on shares of TScan Therapeutics in a report on Tuesday, November 5th. Finally, Needham & Company LLC reaffirmed a “buy” rating and issued a $11.00 price target on shares of TScan Therapeutics in a report on Tuesday, November 12th. Five research analysts have rated the stock with a buy rating, According to MarketBeat.com, TScan Therapeutics currently has a consensus rating of “Buy” and a consensus target price of $12.00.

TScan Therapeutics Stock Performance

NASDAQ:TCRX opened at $4.41 on Friday. The company has a market cap of $233.62 million, a price-to-earnings ratio of -4.16 and a beta of 0.79. TScan Therapeutics has a 1 year low of $3.73 and a 1 year high of $9.69. The stock’s 50 day simple moving average is $5.31 and its two-hundred day simple moving average is $6.48. The company has a debt-to-equity ratio of 0.13, a current ratio of 9.56 and a quick ratio of 7.77.

Insider Buying and Selling

In related news, insider Zoran Zdraveski sold 164,686 shares of the firm’s stock in a transaction that occurred on Friday, August 23rd. The stock was sold at an average price of $5.78, for a total transaction of $951,885.08. Following the completion of the sale, the insider now directly owns 4,716 shares of the company’s stock, valued at approximately $27,258.48. This trade represents a 97.22 % decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Barbara Klencke acquired 5,000 shares of the company’s stock in a transaction that occurred on Monday, September 23rd. The shares were acquired at an average price of $5.29 per share, with a total value of $26,450.00. Following the acquisition, the director now owns 45,000 shares in the company, valued at $238,050. This trade represents a 12.50 % increase in their ownership of the stock. The disclosure for this purchase can be found here. In the last ninety days, insiders bought 15,000 shares of company stock valued at $82,550. Company insiders own 2.76% of the company’s stock.

Institutional Trading of TScan Therapeutics

Large investors have recently made changes to their positions in the stock. Dimensional Fund Advisors LP purchased a new position in TScan Therapeutics in the 2nd quarter worth about $70,000. The Manufacturers Life Insurance Company bought a new position in TScan Therapeutics in the 2nd quarter worth about $90,000. SG Americas Securities LLC purchased a new position in shares of TScan Therapeutics during the third quarter worth approximately $78,000. XTX Topco Ltd bought a new stake in shares of TScan Therapeutics during the third quarter valued at approximately $112,000. Finally, Cornercap Investment Counsel Inc. purchased a new stake in shares of TScan Therapeutics in the second quarter valued at approximately $134,000. 82.83% of the stock is owned by hedge funds and other institutional investors.

TScan Therapeutics Company Profile

TScan Therapeutics, Inc, a clinical-stage biopharmaceutical company, develops T cell receptor-engineered T cell (TCR-T) therapies for the treatment of patients with cancer in the United States. The company's lead product candidates include TSC-100 and TSC-101 that is in Phase I clinical trial for the treatment of patients with hematologic malignancies to eliminate residual disease and prevent relapse after allogeneic hematopoietic cell transplantation.